Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Ivan De Kouchkovsky"'
Autor:
Ivan de Kouchkovsky, Hao Nguyen, Hsin-Yu Chen, Xiaoxi Liu, Hecong Qin, Bradley A. Stohr, Romelyn Delos Santos, Michael A. Ohliger, Zhen Jane Wang, Robert A. Bok, Jeremy W. Gordon, Peder E.Z. Larson, Mary Frost, Kimberly Okamoto, Daniel Gebrezgiabhier, Matthew Cooperberg, Daniel B. Vigneron, John Kurhanewicz, Rahul Aggarwal
Publikováno v:
Journal of Magnetic Resonance Open, Vol 21, Iss , Pp 100165- (2024)
Background: Although multiparametric (mp) 1H magnetic resonance imaging (MRI) is increasingly used to detect and localize prostate cancer (PC), its correlation with tumor grade is limited. Hyperpolarized (HP) carbon-13 (13C) MR is an emerging imaging
Externí odkaz:
https://doaj.org/article/da8c42800e3a40d08d33e33696c21230
Autor:
Tanya Jindal, Xiaolin Zhu, Rohit Bose, Vipul Kumar, Edward Maldonado, Prianka Deshmukh, Chase Shipp, Stephanie Feng, Michelle S. Johnson, Austin Angelidakis, Daniel Kwon, Hala T. Borno, Ivan de Kouchkovsky, Arpita Desai, Rahul Aggarwal, Lawrence Fong, Eric J. Small, Anthony Wong, Sima Porten, Jonathan Chou, Terence Friedlander, Vadim S. Koshkin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundEnfortumab vedotin (EV) is an antibody-drug conjugate approved for patients with treatment-refractory advanced urothelial carcinoma (aUC), however data on biomarkers of response is lacking.MethodsWe retrospectively identified all aUC patien
Externí odkaz:
https://doaj.org/article/807b9f7db97e495ebdc50bd69421c109
Autor:
Li Zhang, Divya Natesan, Lawrence Fong, Emily Chan, David Y Oh, Son Ho, Ivan de Kouchkovsky, Errol J Philip, Francis Wright, Daniel M Kim, Daniel Kwon, Hansen Ho, Sima P Porten, Anthony C Wong, Arpita Desai, Franklin W Huang, Jonathan Chou, Raj S Pruthi, Eric J Small, Terence W Friedlander, Vadim S Koshkin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to
Externí odkaz:
https://doaj.org/article/daffc1a2d771420089913bf03e6aaad2
Autor:
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Albert Jang, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Robert Bruce Montgomery, Petros Grivas, Ali Raza Khaki
Publikováno v:
Clin Genitourin Cancer
Clinical genitourinary cancer, vol 20, iss 5
Clinical genitourinary cancer, vol 20, iss 5
Immune checkpoint inhibitors are a well-established treatment option for advanced urothelial carcinoma, and biomarkers of response are needed for better patient selection. We show that metastatic disease confined to lymph nodes is associated with bet
Autor:
Tanya Jindal, Li Zhang, Prianka Deshmukh, Kevin Reyes, Emily Chan, Vipul Kumar, Xiaolin Zhu, Edward Maldonado, Stephanie Feng, Michelle Johnson, Austin Angelidakis, Daniel Kwon, Arpita Desai, Hala T Borno, Rohit Bose, Anthony Wong, Julian Hong, Peter Carroll, Maxwell Meng, Sima Porten, Rahul Aggarwal, Eric J Small, Lawrence Fong, Jonathan Chou, Terence Friedlander, Ivan de Kouchkovsky, Vadim S Koshkin
Publikováno v:
Clinical Genitourinary Cancer.
Autor:
Rahul Aggarwal, Russell Z. Szmulewitz, Charles J. Ryan, Pamela L. Paris, Lawrence Fong, Terence Friedlander, Eric J. Small, Audrey Phone, Catriona Lewis, Li Zhang, Benedito A. Carneiro, Arpit Rao, Ivan de Kouchkovsky
Supplementary Figure from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd8f76b1393f511af362dcacb326798
https://doi.org/10.1158/1078-0432.22487640.v1
https://doi.org/10.1158/1078-0432.22487640.v1
Autor:
Rahul Aggarwal, Russell Z. Szmulewitz, Charles J. Ryan, Pamela L. Paris, Lawrence Fong, Terence Friedlander, Eric J. Small, Audrey Phone, Catriona Lewis, Li Zhang, Benedito A. Carneiro, Arpit Rao, Ivan de Kouchkovsky
Supplementary Table from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04773b537caa91304d69cf4bcb3ef471
https://doi.org/10.1158/1078-0432.22487631.v1
https://doi.org/10.1158/1078-0432.22487631.v1
Autor:
Rahul Aggarwal, Russell Z. Szmulewitz, Charles J. Ryan, Pamela L. Paris, Lawrence Fong, Terence Friedlander, Eric J. Small, Audrey Phone, Catriona Lewis, Li Zhang, Benedito A. Carneiro, Arpit Rao, Ivan de Kouchkovsky
Purpose:Ribociclib, a CDK4/6 inhibitor, demonstrates preclinical antitumor activity in combination with taxanes. We evaluated the safety and efficacy of ribociclib plus docetaxel in a phase Ib/II study in metastatic castration-resistant prostate canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3996aeb5b831ce93dd1c3ae59561ce1d
https://doi.org/10.1158/1078-0432.c.6532557
https://doi.org/10.1158/1078-0432.c.6532557
Autor:
Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal
Publikováno v:
Clinical Cancer Research. 28:1531-1539
Purpose: Ribociclib, a CDK4/6 inhibitor, demonstrates preclinical antitumor activity in combination with taxanes. We evaluated the safety and efficacy of ribociclib plus docetaxel in a phase Ib/II study in metastatic castration-resistant prostate can
Autor:
Jonathan L. Wright, Alexander Sankin, Petros Grivas, Ignacio Duran, Ali Raza Khaki, Dimitrios Makrakis, Pedro C. Barata, Guru Sonpavde, Benjamin A. Gartrell, Vadim S. Koshkin, Evan Shreck, Lucia Carril-Ajuria, David J. Pinato, Mehmet Asim Bilen, Neeraj Agarwal, Mark P. Lythgoe, Giuseppe Di Lorenzo, Jayanshu Jain, Daniel Castellano, Ivan de Kouchkovsky, Rana R. McKay, Jure Murgic, Tyler F. Stewart, Michael Edward Devitt, Rafee Talukder, Pedro Isaacsson-Velho, Sandy T. Liu, Rafael Morales-Barrera, Lucia Alonso Buznego, Marcus Marie Moses, Leonidas Nikolaos Diamantopoulos, Aristotelis Bamias, Joseph J. Park, Ana Fröbe, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Victor Sacristan Santos, Monika Joshi, Evan Y. Yu, Alejo Rodriguez-Vida, Michael Grant, Ajjai Alva, Christopher J. Hoimes, Abhishek Tripathi
Publikováno v:
BJU international, vol 130, iss 5
BJU Int
BJU Int
OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64617a8b9d10e6092cd0be747466efd
https://escholarship.org/uc/item/8678m8j9
https://escholarship.org/uc/item/8678m8j9